ScripBiotechnology valuations generally have been on the rise in recent months, relative to general stock market indices, but there still are a number of drug developers that are having trouble gaining tra
ScripDespite missing out on a proposed acquisition priced at about four times its share price at the time of offer, TherapeuticsMD Inc. has found an exit for its shareholders by selling off its women’s h
ScripA drug developer went public in the US for the first time in more than two months when MAIA Biotechnology, Inc. raised $10m from the sale of 2 million shares at $5 each on 27 July, taking advantage
ScripNeuraxpharm Takes On Established Products From Sanofi Central nervous system specialist Neuraxpharm Arzneimittel GmbH , headquartered in Dusseldorf and Barcelona, announced 12 July that it is strengt